A Novel Genetic Mechanism of Caplacizumab Resistance in iTTP – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Mari Thomas et al., adding:
“Caplacizumab Resistance in Immune Thrombotic Thrombocytopenic Purpura (iTTP) Associated with VWF A1 Domain Missense Variant
This landmark first report describes caplacizumab resistance in an iTTP patient caused by a VWF A1 domain missense variant (P1266L) that impairs drug binding, revealing a novel genetic mechanism of treatment failure beyond premature therapy discontinuation.”
Title: Caplacizumab resistance in immune thrombotic thrombocytopenic purpura is associated with a von Willebrand factor A1 domain missense variant
Authors: Mari Thomas, Imogen Buckle, Adela Constantinescu-Bercu, Rens De Groot, Sabina McCann, Marie Scully
Read the Full Article on JTH
Other articles about Journal of Thrombosis and Haemostasis
-
May 18, 2026, 14:47Ting Yuan: Understanding the Complexity Behind Repeated IVF Failure
-
May 18, 2026, 14:33Global Resolution on Advancing Comprehensive Care and Health Equity for People with Bleeding Disorders Worldwide at the 79th WHA – WFH
-
May 18, 2026, 14:25Salih Ehsan: Key Diagnostic Clues in Thalassemia Minor
-
May 18, 2026, 14:02Matteo Foschi: A Global Gathering for Stroke Innovation and Research at ESOC 2026
-
May 18, 2026, 14:01Who is the NBA? – Haemophilia Foundation Australia
-
May 18, 2026, 14:00Julie Makani: Partnership between Tanzania and the USA – Health Sciences
-
May 18, 2026, 13:58Alejandro González Veliz: Cardiology Enters the Era of Inflammation
-
May 18, 2026, 13:50Arshad-Ali Auhammad: Celebrating Youth Leadership in the Global Bleeding Disorders Community
-
May 18, 2026, 13:36Zain Khalpey: In Cardiovascular Medicine Flow Is Everything